Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:22:30.900Z.
Calculation as of: 2026-10-06T18:22:30.900Z.
Quote observation: 2026-10-06T18:13:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9eb175beb73ea6d5bc2b5d4e57ff3726ad64c6dbf03440990cee379981bf6545
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$108729.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$71110.00
EV/Sales Ratio
N/A
TTM Avg
159.76x
3Y Avg
159.76x
5Y Avg
159.76x
Market Cap
$30509.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6102.00
EV/Sales Ratio
N/A
TTM Avg
7806.53x
3Y Avg
7806.53x
5Y Avg
7806.53x
Market Cap
$380715.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Psyence Biomedical Ltd. (PBM) | $97282.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108729.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $71110.00 | N/A | 159.76x | 159.76x | 159.76x |
| Akanda Corp. (AKAN)vs › | $61495.00 | N/A | N/A | N/A | N/A |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | N/A | N/A | N/A | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30509.00 | N/A | N/A | N/A | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6102.00 | N/A | 7806.53x | 7806.53x | 7806.53x |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
